EXTON, Pa., Sept. 15 ViroPharma Incorporated (Nasdaq: VPHM) today announced that the company will be presenting at several upcoming healthcare investment conferences.
Advertisement
Vincent Milano, president and chief executive officer of ViroPharma, will present at the Bank of America Securities/Merrill Lynch 2009 S/Mid Cap Conference at 9:40 A.M. ET on Monday, September 21, 2009. The conference is being held at the InterContinental Hotel in Boston.
Advertisement
Charles Rowland, vice president and chief financial officer of ViroPharma, will present at the 2009 UBS Global Life Sciences Conference at 12:30 P.M ET on Wednesday, September 23, 2009. The conference is being held at the Grand Hyatt in New York City.
Richard Morris, chief accounting officer of ViroPharma will present at 2009 Maxim Group Growth Conference at 10:30 A.M. ET on Tuesday, September 29. 2009. The conference is being held at the Grand Hyatt in New York City.
Mr. Milano will also present at the Fourth Annual JMP Securities Healthcare Focus Conference at 2:00 P.M ET on Tuesday, October 6, 2009. The conference is being held at the New York Palace Hotel.
ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.
About ViroPharma Incorporated
ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.
ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.
SOURCE ViroPharma Incorporated
